Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers 2021, 13, 1612

The authors wish to make the following corrections to this paper [1]: In the published version, Figure 4 appeared as a duplication of Figure 1b. Furthermore, the legend of Figure 2 has been corrected to accurately reflect the data shown.

The correct version of Figure 2 is as follows:

Figure 2.

KRAS mutation status was determined in plasma from (a) sporadic PDAC cases (b) hereditary or familial PDAC (H/FPC) cases via BEAMing and mutant KRAS was more frequently detected in sporadic cases compared to H/FPC cases. BEAMing was performed using cfDNA isolated from 1 mL of plasma from 54 PDAC cases (31 familial cases and 23 sporadic cases). The frequency of mutant KRAS was 70% in sporadic cases and 16% in familial cases, which was statistically significant (p ≤ 0.001).

The correct version of Figure 4 is as follows:

Figure 4.

Hereditary or familial PDAC cases have a longer overall survival (OS) compared to sporadic cases.

We stress that these errors were purely due to human error and oversight; the corrections made do not affect or change the written portion of the figure legend, the interpretation of the results, or the final conclusions of this manuscript. The manuscript will be updated. The authors would like to apologize for any inconvenience caused. All changes have been reviewed and verified by the Academic Editors.

Author Contributions

Conceptualization, J.E. and A.C.; Data curation, J.E., E.B., M.E.C., R.F. (Raquel Fuentes), M.R.-G., R.F. (Reyes Ferreiro), P.R., G.M., D.G.-S., J.V.L., B.S.J., N.M. and A.C.; Funding acquisition, A.C.; Methodology, J.E., E.B., M.E.C., G.M. and D.G.-S.; Writing—original draft, J.E., E.B., M.E.C. and A.C.; Writing—review & editing, J.E., R.F. (Raquel Fuentes), M.R.-G., R.F. (Reyes Ferreiro), P.R., G.M., D.G.-S., J.V.L., B.S.J., N.M. and A.C. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I+D+i 2013-2016): ISCIII (PI09/02221, PI12/01635, PI15/02101 and PI18/0135) and co-financed by the European Development Regional Fund ‘‘A way to achieve Europe’’ (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073), La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016), Fundación Mutua Madrileña (FMM)/XVI Convocatoria de Ayudas a la Investigación en Salud and Asociación Cáncer de Páncreas (ACanPan); Asociación Española de Pancreatología (AESPANC)/IV Becas de Investigación Carmen Delgado/Miguel Pérez-Mateo.

Conflicts of Interest

The authors declare no conflict of interest.